SLC5A2 and Hyperglycemia: Sodium–glucose cotransporter 2 (SGLT2) inhibitors, a new class of oral hypoglycemic agents, ameliorate hyperglycemia by inhibiting glucose reabsorption in the proximal tubule of the kidney, thereby functioning in an insulin-independent manner (DeFronzo et al., 2017).